Article

Prostate Ca screening interval of 4 years misses few cancers

A 4-year screening interval was found adequate for detecting most cancersin a large European randomized trial of prostate cancer screening, accordingto a study in the Oct. 1 issue of the Journal of the National CancerInstitute (2003; 95:1462-6).

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Related Content
Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation
Published: October 4th 2024 | Updated: October 4th 2024

Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation

Urology Times staff
"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 3rd 2024

Ra223 plus SABR does not delay progression of oligometastatic HSPC

Benjamin P. Saylor
"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
October 3rd 2024

Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC

Hannah Clarke
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT
October 3rd 2024

MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT

Hannah Clarke
“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote.
© 2024 MJH Life Sciences

All rights reserved.